Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Latest shares articles
Eurozone CPI holds steady, reinforcing ECB’s wait-and-see approach
Eurozone inflation remained unchanged in July which enabled the European Central Bank to keep rates unchanged for the foreseeable future
21 hours ago
Amazon Q2 Earnings Preview: tariffs, mixed demand and AWS under scrutiny
Signs of further AI monetisation could push Amazon shares towards all time highs.
14:02, 31 July 2025
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
13:08, 31 July 2025
US labour data could give more context to a stronger-than-expected GDP in Q2
The US labour market is expected to have cooled in July as a stronger-than-expected Q2 GDP print surprised markets
12:17, 31 July 2025
Ratings and Reviews
Ratings and Reviews
